Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SQ-001 Dose Escalation in Healthy Volunteers
NCT04026321Phase 1Completed
- Sponsor
- Livzon Pharmaceutical Group Inc.
- Start
- Oct 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of shenqi fuzheng injection in solid tumor (5 arms), sponsored by Livzon Pharmaceutical Group Inc. Primary endpoints: Maximum Observed Plasma Concentration at Day 2, Time to Reach Cmax at Day 2 and 4 more. Started Oct 2018; status: completed.
02
Drugs
shenqi fuzheng injection
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04026321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04026321.